<DOC>
	<DOCNO>NCT03055234</DOCNO>
	<brief_summary>This multicenter , randomize ( 2:1 ; oral treprostinil : placebo ) , double-blind , placebo-controlled event-driven ( time pulmonary hypertension [ PH ] clinical worsening ) study subject PH associate sickle cell disease ( SCD ) . Once enrol , subject evaluate Weeks 6 , 12 , 24 , every 12 week duration study . Subjects permit enter 48-week open-label extension period experience PH clinical worsening event .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Oral Treprostinil Subjects With Pulmonary Hypertension ( PH ) Associated With Sickle Cell Disease ( SCD )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . The subject must diagnosis SCD confirm hemoglobin electrophoresis . 2 . The subject diagnosis symptomatic World Health Organization ( WHO ) Group 5.1 chronic hemolytic anemia PH . 3 . The subject must Baseline 6MWD great 150 meter , absence concurrent injury , illness , confound factor . 4 . The subject pulmonary function test conduct within 6 month Screening Screening period . 5 . The subject must stable dos medical therapy least 30 day prior randomization dose adjustment , addition , discontinuation . 6 . The subject must optimally treated conventional PH therapy least 10 day prior randomization addition , discontinuation , dose change . 7 . Subjects receive endothelin receptor antagonist ( ERA ) must receive therapy great 90 day , reach maintain stable dose minimum 30 day prior randomization . 8 . Subjects receive calcium channel blocker must stable dose minimum 3 month prior randomization . 1 . The subject pregnant lactating . 2 . The subject previously receive oral treprostinil receive phosphodiesterase type 5 inhibitor ( PDE5I ) . 3 . The subject receive prostacyclin within 30 day prior start study , previous intolerance significant lack efficacy prostacyclin prostacyclin analogue result discontinuation inability titrate therapy effectively . 4 . The subject background conventional therapy PH add , remove , dos adjust within 10 day prior randomization . 5 . The subject disease associate pulmonary arterial hypertension ( PAH ) . 6 . The subject vasoocclusive crisis , acute chest syndrome event , unscheduled transfusion within 30 day randomization . 7 . The subject history ischemic heart disease , include previous myocardial infarction symptomatic coronary artery disease , within 6 month prior Screening leave ventricular ejection fraction le 40 % assess either multigated angiogram ( MUGA ) , angiography , echocardiogram . 8 . The subject alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level 3 time great upper limit normal , clinically significant liver disease/dysfunction , know ChildPugh Class B C hepatic disease Screening . 9 . The subject chronic renal insufficiency , define requirement dialysis . 10 . The subject musculoskeletal disorder , disease likely limit ambulation , connect machine portable . 11 . The subject unstable psychiatric condition mentally incapable understand objective , nature , consequence study , condition Investigator 's opinion would constitute unacceptable risk subject 's safety . 12 . The subject receive investigational drug , investigational device place , participate investigational drug device study within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oral treprostinil</keyword>
	<keyword>6-Minute Walk Distance</keyword>
	<keyword>PH</keyword>
	<keyword>sickle cell</keyword>
</DOC>